Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukaemia: Results of the UK Medical Research Council AML-R trial.

被引：0

作者：

Yin, JAL

Wheatley, K

Rees, J

Burnett, A

机构：

[1] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England

[2] CTSU Oxford, Oxford, England

[3] Addenbrookes Hosp, Cambridge, England

[4] Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales

来源：

BLOOD | 1998年 / 92卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

946

引用

页码：231A / 231A

页数：1

共 50 条

[41] Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial
Othman, Jad
Dillon, Richard
Wilhelm-Benartzi, Charlotte
Knapper, Steve
Batten, Leona M.
Canham, Joanna
Hinson, Emily L.
Villiers, William
Kleeman, Michelle
Gilkes, Amanda
Potter, Nicola
Overgaard, Ulrik Malthe
Mehta, Priyanka
Kottaridis, Panos
Cavenagh, Jamie
Hemmaway, Claire
Arnold, Claire
Dennis, Mike
Russell, Nigel H.
BLOOD, 2022, 140 : 1036 - 1038
[42] Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party
Wheatley, Keith
Goldstone, Anthony H.
Littlewood, Tim
Hunter, Anne
Burnett, Alan K.
BRITISH JOURNAL OF HAEMATOLOGY, 2009, 146 (01) : 54 - 63
[43] Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial.
Mueller-Tidow, C.
Bug, Gesine
Schlenk, Richard
Luebbert, Michael
Kraemer, Alwin
Krauter, Juergen
Nachbaur, David
Valent, Peter
Taube, Tillmann
Munzert, Gerd
Lee, Kang-Hun
Dohner, Hartmut
BLOOD, 2008, 112 (11) : 1021 - 1021
[44] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial (vol 20, pg 986, 2019)
Cortes, J. E.
Khaled, S.
Martinelli, G.
LANCET ONCOLOGY, 2019, 20 (07): : E346 - E346
[45] Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial.
De Botton, Stephane
Risueno, Alberto
Schuh, Andre C.
Lowenberg, Bob
Kim, Hee-Je
Vyas, Paresh
Wei, Andrew H.
Stein, Eytan M.
Dohner, Hartmut
Fathi, Amir Tahmasb
Dinardo, Courtney Denton
Regueira, Patricia Martin
Taningco, Lilia
Bluemmert, Iryna
Yu, Xin
See, Wendy L.
Hasan, Maroof
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial
Pandit-Taskar, Neeta
Natwa, Mona
Chen, Ming-Kai
Wagner, Robert
Yap, Wendell
Griffeth, Landis
Wiseman, Gregory
Mhlanga, Joyce
Wahl, Richard
Avril, Norbert
Lamonica, Dominick
Vesselle, Hubert
Chasen, Beth
Johnson, Craig
Hansen, Neil
Leung, Eugene
Osborne, Joseph
Peterson, Jennifer
Menda, Yusuf
Franceschi, Dinko
Desai, Avinash
Brodin, Patrik
Haeuber, Elaina
Nahar, Akash
Passalaqua, Susan
JOURNAL OF NUCLEAR MEDICINE, 2023, 64
[47] Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
Cunningham, David
Stenning, Sally P.
Smyth, Elizabeth C.
Okines, Alicia F.
Allum, William H.
Rowley, Sam
Stevenson, Laura
Grabsch, Heike I.
Alderson, Derek
Crosby, Thomas
Griffin, S. Michael
Mansoor, Wasat
Coxon, Fareeda Y.
Falk, Stephen J.
Darby, Suzanne
Sumpter, Kate A.
Blazeby, Jane M.
Langley, Ruth E.
LANCET ONCOLOGY, 2017, 18 (03): : 357 - 370
[48] Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
Ganguly, Siddhartha
Cortes, Jorge E.
Kraemer, Alwin
Levis, Mark J.
Martinelli, Giovanni
Pert, Alexander E.
Russell, Nigel H.
Arunachalam, Meena
Gammon, Guy
Lesegretain, Arnaud
Mires, Derek E.
Khaled, Samer K.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S8 - S8
[49] Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial
Ganguly, Siddhartha
Cortes, Jorge E.
Kramer, Alwin
Levis, Mark J.
Martinelli, Giovanni
Perl, Alexander E.
Russell, Nigel H.
Arunachalam, Meena
Gammon, Guy
Lesegretain, Arnaud
Mires, Derek E.
Namuyinga, Ruth
Zhang, Yufen
Khaled, Samer K.
BLOOD, 2019, 134
[50] Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, MutantIDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
DiNardo, Courtney D.
de Botton, Stephane
Risueno, Alberto
Schuh, Andre C.
Loewenberg, Bob
Kim, Hee-Je
Vyas, Paresh
Wei, Andrew H.
Stein, Eytan M.
Dohner, Hartmut
Fathi, Amir T.
Martin-Regueira, Patricia
Taningco, Lilia
Bluemmert, Iryna
Yu, Xin
See, Wendy L.
Hasan, Maroof
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S249 - S250

← 1 2 3 4 5 →